GENSCRIPT BIO (01548) plans to spin off its subsidiary, Hongbo Biotechnology, and list it independently on the main board of the Hong Kong Stock Exchange.

08:20 04/09/2026

Kingsray Biotech (01548) announced that the company intends to spin off Probio Technology Limited (Pengbo Bio, an indirect non-wholly owned subsidiary of the company responsible for the group's contract research, development, and manufacturing organization services in biopharmaceuticals and advanced therapies) and independently list its shares on the main board of the Stock Exchange.

GENSCRIPT BIO (01548) announced that the company recommends the spin-off of Probio Technology Limited (Probio Bio), an indirect non-wholly owned subsidiary of the company responsible for the group's biological formulation and advanced therapy contract research, development, and production organization services, and to list its shares independently on the main board of the Hong Kong Stock Exchange. Regarding the proposed spin-off, the company has submitted an application to the Stock Exchange in accordance with the 15th guidance note. On August 14, 2026, the Listing Committee confirmed that the company could proceed with the proposed spin-off.

A-shares midday | Three major indices surged and then retreated, closing higher collectively, led by AI applications and digital currency.

HK Stock Market Move | SIHUAN PHARM (00460) rose nearly 4% in the morning as Xuan Bamboo Biotechnology reached a commercial cooperation agreement with INNOBIC for the marketing of Pirfenidone in the Thai market.

HK Stock Market Move | Huaxin Building Materials Group (06655) rose more than 7% in early trading as overseas capacity expansion reshapes its profit structure. The company is transitioning to a global building materials platform.

A-shares midday | Three major indices surged and then retreated, closing higher collectively, led by AI applications and digital currency.